Drug intelligence / Profile preview

Evafem

Development stage: Unknown
Lead developer: Andromaco
Modality: Small Molecules
Administration: Oral

Overview

Evafem is a combined oral contraceptive available as coated tablets, containing clormadinone acetate and ethinyl estradiol. It is primarily used for the prevention of pregnancy. The drug works by leveraging the progestogenic and antiandrogenic effects of clormadinone acetate, combined with the estrogenic effects of ethinyl estradiol, to inhibit ovulation, alter cervical mucus, and modify the endometrial lining, thereby preventing conception. It may also be used in the management of certain dermatological conditions like moderate acne due to the anti-androgenic properties of clormadinone.

Brand names: EvafemEvafem 20Evafem20Evafem-20
Other names: Clormadinone + Ethinyl estradiol

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on Evafem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evafem.

Explore the full profile